

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 15 of 22 returned.**☐ 1. Document ID: US 20020032171 A1

L1: Entry 1 of 22

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020032171

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020032171 A1

TITLE: Clear oil-containing pharmaceutical compositions containing a therapeutic agent

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chen, Feng-Jing	Salt Lake City	UT	US	
Patel, Mahesh V.	Salt Lake City	UT	US	
Fikstad, David T.	Salt Lake City	UT	US	

US-CL-CURRENT: 514/54; 424/727, 424/731, 424/750, 424/757

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
Image												

☐ 2. Document ID: US 20020028243 A1

L1: Entry 2 of 22

File: PGPB

Mar 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020028243

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020028243 A1

TITLE: Protein matrix materials, devices and methods of making and using thereof

PUBLICATION-DATE: March 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Masters, David B.	Hastings	MN	US	

US-CL-CURRENT: 424/484

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
Image												

☐ 3. Document ID: US 20020028235 A1

L1: Entry 3 of 22

File: PGPB

Mar 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020028235
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020028235 A1

TITLE: Dermal penetration enhancers and drug delivery systems involving same

PUBLICATION-DATE: March 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reed, Barry Leonard	Strathmore		AU	
Morgan, Timothy Matthias	Parkville		AU	
Finnin, Barrie Charles	Glen Iris		AU	

US-CL-CURRENT: 424/449; 514/539

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 4. Document ID: US 20020012680 A1

L1: Entry 4 of 22

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020012680
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020012680 A1

TITLE: Compositions and methods for improved delivery of lipid regulating agents

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Patel, Mahesh V.	Salt Lake City	UT	US	
Chen, Feng-Jing	Salt Lake City	UT	US	

US-CL-CURRENT: 424/400

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 5. Document ID: US 20010023261 A1

L1: Entry 5 of 22

File: PGPB

Sep 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010023261
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010023261 A1

TITLE: Novel composition for the transdermal administration of drugs

PUBLICATION-DATE: September 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ryoo, Je-Phil	Daejeon		KR	
Choi, Mi-Suk	Daejeon		KR	
Choi, Jong-Kun	Daejeon		KR	

US-CL-CURRENT: 514/772; 514/777

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Desc
Image												

☐ 6. Document ID: US 20010018073 A1

L1: Entry 6 of 22

File: PGPB

Aug 30, 2001

PGPUB-DOCUMENT-NUMBER: 20010018073

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010018073 A1

TITLE: Transdermal compositions with enhanced skin penetration properties

PUBLICATION-DATE: August 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dittgen, Michael	Apolda		DE	
Fricke, Sabine	Jena		DE	
Volkel, Christoph	Jena		DE	
Ahrens, Kathrin	Reinheim		DE	
Gerecke, Hagen	Jena		DE	
Kopke, Kai	Triengen		CH	

US-CL-CURRENT: 424/486

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Desc
Image												

☐ 7. Document ID: US 20010009673 A1

L1: Entry 7 of 22

File: PGPB

Jul 26, 2001

PGPUB-DOCUMENT-NUMBER: 20010009673

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010009673 A1

TITLE: TRANSDERMAL THERAPEUTIC SYSTEMS

PUBLICATION-DATE: July 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LIPP, RALPH	BERLIN		DE	
GUNTHER, CLEMENS	BERLIN		DE	

US-CL-CURRENT: 424/400

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 8. Document ID: US 6299900 B1

L1: Entry 8 of 22

File: USPT

Oct 9, 2001

US-PAT-NO: 6299900

DOCUMENT-IDENTIFIER: US 6299900 B1

TITLE: Dermal penetration enhancers and drug delivery systems involving same

DATE-ISSUED: October 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Reed; Barry Leonard	Strathmore			AUX
Morgan; Timothy Matthias	Parkville			AUX
Finnin; Barrie Charles	Glen Iris			AUX

US-CL-CURRENT: 424/449; 424/448, 514/947, 602/41, 604/307

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 9. Document ID: US 6294192 B1

L1: Entry 9 of 22

File: USPT

Sep 25, 2001

US-PAT-NO: 6294192

DOCUMENT-IDENTIFIER: US 6294192 B1

TITLE: Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Patel; Mahesh V.	Salt Lake City	UT		
Chen; Feng-Jing	Salt Lake City	UT		

US-CL-CURRENT: 424/451; 424/450, 424/464, 424/489, 514/772, 514/937, 514/962, 514/963, 514/975

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 10. Document ID: US 6267985 B1

L1: Entry 10 of 22

File: USPT

Jul 31, 2001

US-PAT-NO: 6267985

DOCUMENT-IDENTIFIER: US 6267985 B1

TITLE: Clear oil-containing pharmaceutical compositions

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chen; Feng-Jing	Salt Lake City	UT		
Patel; Mahesh V.	Salt Lake City	UT		

US-CL-CURRENT: 424/451; 424/43, 424/433, 424/436, 424/441, 424/443, 424/455, 424/456,
424/458, 424/463, 424/464, 424/465, 424/489, 424/490, 424/731, 424/735, 424/750,
424/757, 424/764, 514/44, 514/772.2, 514/772.3, 514/777, 514/778, 514/779, 514/781,
514/783, 514/784, 514/785, 514/786, 514/937, 514/944

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 11. Document ID: US 6238284 B1

L1: Entry 11 of 22

File: USPT

May 29, 2001

US-PAT-NO: 6238284

DOCUMENT-IDENTIFIER: US 6238284 B1

TITLE: Transdermal compositions with enhanced skin penetration properties

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dittgen; Michael	Apolda			DEX
Fricke; Sabine	Jena			DEX
Volkel; Christoph	Jena			DEX
Ahrens; Kathrin	Reinheim			DEX
Gerecke; Hagen	Jena			DEX
Kopke; Kai	Triengen			CHX

US-CL-CURRENT: 156/325; 156/283, 156/327, 424/443, 424/448

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 12. Document ID: US 6153216 A

L1: Entry 12 of 22

File: USPT

Nov 28, 2000

US-PAT-NO: 6153216

DOCUMENT-IDENTIFIER: US 6153216 A

TITLE: Transdermal estradiol/progestogen agent patch and its production

DATE-ISSUED: November 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cordes; Gunter	Lagenfeld			DEX
Santoro; Antonino	Monza			ITX
Setnikar; Ivo	Monza			ITX

US-CL-CURRENT: 424/449; 424/448, 514/691, 514/731, 602/41, 602/60, 604/307, 604/892.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 13. Document ID: US 6074665 A

L1: Entry 13 of 22

File: USPT

Jun 13, 2000

US-PAT-NO: 6074665

DOCUMENT-IDENTIFIER: US 6074665 A

TITLE: Transdermal therapeutic system for administering active agents to the human body via the skin

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Horstmann; Michael	Neuwied			DEX
Leonhard; Johannes	Bendorf			DEX
Muller; Walter	Neuwied			DEX

US-CL-CURRENT: 424/449; 424/448

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 14. Document ID: US 5906830 A

L1: Entry 14 of 22

File: USPT

May 25, 1999

US-PAT-NO: 5906830

DOCUMENT-IDENTIFIER: US 5906830 A

TITLE: Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

DATE-ISSUED: May 25, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Farinas; Kathleen C.	Belmont	CA		
Miller; Chad M.	Durham	NC		
Soni; Pravin L.	Sunnyvale	CA		

US-CL-CURRENT: 424/448; 424/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw	Desc
Image													

☐ 15. Document ID: US 5830505 A

L1: Entry 15 of 22

File: USPT

Nov 3, 1998

US-PAT-NO: 5830505

DOCUMENT-IDENTIFIER: US 5830505 A

TITLE: Active ingredient patch

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fischer; Wilfried	Holzkirchen			DEX
Klokkers; Karin	Holzkirchen			DEX

US-CL-CURRENT: 424/487; 424/449, 424/486

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw	Desc
Image													

[Generate Collection](#)[Print](#)

Term	Documents
TRANSDERMAL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	19898
TRANSDERMALS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	10
PATCH.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	43430
PATCHES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	25683
PALSTER.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	9
PALSTERS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
SUPERSATURAT\$4	0
SUPERSATURAT.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	34
SUPERSATURATE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	320
SUPERSATURATECT.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
SUPERSATURATED.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	6983
((((TRANSDERMAL OR PATCH OR PALSTER))AND (SUPERSATURAT\$4 OR SARURAT\$4 OR OVERSATURAT\$4 OR OVER SATURAT\$4)) AND (ESTROGEN OR EOSTROGEN OR ESTRADIOL OR OESTRADIOL) AND NORETHISTERONE)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	22

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

-

[Change Format](#)

[Previous Page](#)

[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 16 through 22 of 22 returned.**☐ 16. Document ID: US 5683711 A

L1: Entry 16 of 22

File: USPT

Nov 4, 1997

US-PAT-NO: 5683711

DOCUMENT-IDENTIFIER: US 5683711 A

TITLE: Active ingredient patch

DATE-ISSUED: November 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fischer; Wilfried	Holzkirchen			DEX
Klokke; Karin	Holzkirchen			DEX

US-CL-CURRENT: 424/449; 424/487

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 17. Document ID: US 5676968 A

L1: Entry 17 of 22

File: USPT

Oct 14, 1997

US-PAT-NO: 5676968

DOCUMENT-IDENTIFIER: US 5676968 A

TITLE: Transdermal therapeutic systems with crystallization inhibitors

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lipp; Ralph	Berlin			DEX
Riedl; Jutta	Berlin			DEX
Tack; Johannes	Berlin			DEX

US-CL-CURRENT: 424/448; 424/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 18. Document ID: US 5662923 A

L1: Entry 18 of 22

File: USPT

Sep 2, 1997

US-PAT-NO: 5662923

DOCUMENT-IDENTIFIER: US 5662923 A

TITLE: Plaster for the transdermal application of steroid hormones, containing dexpantenol

DATE-ISSUED: September 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roreger; Michael	Neuwied			DEX

US-CL-CURRENT: 424/445; 424/448, 424/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 19. Document ID: US 5352457 A

L1: Entry 19 of 22

File: USPT

Oct 4, 1994

US-PAT-NO: 5352457

DOCUMENT-IDENTIFIER: US 5352457 A

TITLE: Transdermal device

DATE-ISSUED: October 4, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jenkins; Anthony W.	Comberton			GBX

US-CL-CURRENT: 424/448; 424/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 20. Document ID: DE 59901355 G, DE 19828274 A1, WO 9966907 A1, AU 9945087 A, EP 1089720 A1, EP 1089720 B1

L1: Entry 20 of 22

File: DWPI

Jun 6, 2002

DERWENT-ACC-NO: 2000-107240

DERWENT-WEEK: 200237

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Transdermal patch for controlled release of estradiol and norethisterone acetate with reservoir based on polyacrylate adhesive and containing terpolymer crystallization inhibitor

INVENTOR: ROVATI, L; SANTORO, A

PATENT-ASSIGNEE:

ASSIGNEE	CODE
ROTTAPHARM BV	ROTTN
ROTAPHARM BV	ROTAN

PRIORITY-DATA: 1998DE-1028274 (June 25, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 59901355 G	June 6, 2002		000	A61K009/70
DE 19828274 A1	December 30, 1999		004	A61L015/44
WO 9966907 A1	December 29, 1999	G	000	A61K009/70
AU 9945087 A	January 10, 2000		000	A61K009/70
EP 1089720 A1	April 11, 2001	G	000	A61K009/70
EP 1089720 B1	May 2, 2002	G	000	A61K009/70

DESIGNATED-STATES: AU BR CA CN CZ HU IL IN JP KR LT LV MX NZ PL RU SG SI SK US ZA AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE AT BE CH CY DE DK ES FI FR GB GR IE
IT LI LT LU LV MC NL PT SE SI AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL
PT SE SI

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 59901355G	June 8, 1999	1999DE-0501355	
DE 59901355G	June 8, 1999	1999EP-0927905	
DE 59901355G	June 8, 1999	1999WO-EP03923	
DE 59901355G		EP 1089720	Based on
DE 59901355G		WO 9966907	Based on
DE 19828274A1	June 25, 1998	1998DE-1028274	
WO 9966907A1	June 8, 1999	1999WO-EP03923	
AU 9945087A	June 8, 1999	1999AU-0045087	
AU 9945087A		WO 9966907	Based on
EP 1089720A1	June 8, 1999	1999EP-0927905	
EP 1089720A1	June 8, 1999	1999WO-EP03923	
EP 1089720A1		WO 9966907	Based on
EP 1089720B1	June 8, 1999	1999EP-0927905	
EP 1089720B1	June 8, 1999	1999WO-EP03923	
EP 1089720B1		WO 9966907	Based on

INT-CL (IPC): A61 K 9/70; A61 K 31/565; A61 L 15/44; A61 L 15/58

ABSTRACTED-PUB-NO: DE 19828274A

BASIC-ABSTRACT:

NOVELTY - Transdermal patch for controlled release of estradiol (I) and norethisterone acetate (II) comprises a backing layer, a reservoir supersaturated with the active ingredients and comprises a polyacrylate adhesive and crystallization inhibitor which is a terpolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, especially in 1:2:1 molar ratio, and release liner.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - The patch can be used for therapeutic purposes in human medicine (no further details given).

ADVANTAGE - The crystallization inhibitor inhibits crystallization of (I) and (II) in the reservoir.

ABSTRACTED-PUB-NO:

EP 1089720B

EQUIVALENT-ABSTRACTS:

NOVELTY - Transdermal patch for controlled release of estradiol (I) and norethisterone acetate (II) comprises a backing layer, a reservoir supersaturated with the active ingredients and comprises a polyacrylate adhesive and crystallization inhibitor which is a terpolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, especially in 1:2:1 molar ratio, and release liner.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - The patch can be used for therapeutic purposes in human medicine (no further details given).

ADVANTAGE - The crystallization inhibitor inhibits crystallization of (I) and (II) in the reservoir.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: TRANSDERMAL PATCH CONTROL RELEASE OESTRADIOL NORETHISTERONE ACETATE RESERVOIR BASED POLYACRYLATE ADHESIVE CONTAIN TERPOLYMER CRYSTAL INHIBIT

DERWENT-CLASS: A14 A96 B07 D22 P34

CPI-CODES: A04-F04B; A04-F06E5; A12-V01; B01-A02; B04-C03B; B12-M02F; D09-C04B;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

H7 H714 H721 J0 J011 J2 J271 M210 M211 M213

M232 M262 M272 M281 M320 M423 M431 M510 M520 M530

M540 M782 M905 Q261 R041

Specific Compounds

A01SIK A01SIM

Chemical Indexing M1 *02*

Fragmentation Code

M423 M431 M782 M905 Q261 R041

Specific Compounds

A14FWK A14FWM

Chemical Indexing M1 *03*

Fragmentation Code

H7 H714 H721 J0 J011 J1 J171 M210 M212 M262

M281 M320 M423 M431 M510 M520 M530 M540 M782 M904

M905 Q261 R041

Specific Compounds

A02L0K A02L0M A037TK A037TM

Chemical Indexing M6 *04*

Fragmentation Code

M905 Q261 R041 R111 R263 R303

Chemical Indexing M5 *05*

Fragmentation Code

M431 M782 M904 M905 M910 P622 Q233 R041

Specific Compounds
00014K 00014T 00014M
Registry Numbers
0014U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0014U

ENHANCED-POLYMER-INDEXING:


Polymer Index [1.1] 018 ; G0260*R G0022 D01 D12 D10 D26 D51 D53 ; H0000 ; S9999 S1014*R ; S9999 S1627 S1605 ; P0088 Polymer Index [1.2] 018 ; ND01 ; Q9999 Q8037 Q7987 Polymer Index [1.3] 018 ; Q9999 Q6644*R ; Q9999 Q6666 Q6644 ; B9999 B4988*R B4977 B4740 ; K9869 K9847 K9790 Polymer Index [2.1] 018 ; G0395*R G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53 D58 D63 D88 F41 F89 ; R00479 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53 D58 D63 D85 F41 F89 ; R01606 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53 D58 D63 D88 F08 F07 F41 F89 ; H0033 H0011 ; P0088 Polymer Index [2.2] 018 ; ND01 ; Q9999 Q8037 Q7987

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-032458

Non-CPI Secondary Accession Numbers: N2000-082369

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

 21. Document ID: DE 59901202 G, DE 19828273 A1, WO 9966901 A2, AU 9945086 A, EP 1089719 A2, BR 9912210 A, CZ 200004798 A3, ZA 200007751 A, KR 2001053132 A, CN 1310616 A, HU 200102498 A2, EP 1089719 B1

L1: Entry 21 of 22

File: DWPI

May 16, 2002

DERWENT-ACC-NO: 2000-107239

DERWENT-WEEK: 200240

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Transdermal patch useful for controlled release of estradiol and norethisterone acetate

INVENTOR: KLEIN, R P; MECONI, R ; MUELLER, W ; KLEIN, R

PATENT-ASSIGNEE:

ASSIGNEE

CODE

LTS LOHMANN THERAPIE-SYSTEME GMBH & CO

LOHM

PRIORITY-DATA: 1998DE-1028273 (June 25, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 59901202 G	May 16, 2002		000	A61K009/70
DE 19828273 A1	December 30, 1999		004	A61L015/44
WO 9966901 A2	December 29, 1999	G	000	A61K009/00
AU 9945086 A	January 10, 2000		000	A61K009/00
EP 1089719 A2	April 11, 2001	G	000	A61K009/70
BR 9912210 A	April 10, 2001		000	A61K009/00
CZ 200004798 A3	May 16, 2001		000	A61K009/70
ZA 200007751 A	September 26, 2001		030	A61K000/00
KR 2001053132 A	June 25, 2001		000	A61K009/70
CN 1310616 A	August 29, 2001		000	A61K009/70
HU 200102498 A2	November 28, 2001		000	A61K009/00
EP 1089719 B1	April 10, 2002	G	000	A61K009/70

DESIGNATED-STATES: AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA AT BE CH CY DE
 DK ES FI FR GB GR IE IT LU MC NL PT SE AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE
 AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 59901202G	June 8, 1999	1999DE-0501202	
DE 59901202G	June 8, 1999	1999EP-0927904	
DE 59901202G	June 8, 1999	1999WO-EP03922	
DE 59901202G		EP 1089719	Based on
DE 59901202G		WO 9966901	Based on
DE 19828273A1	June 25, 1998	1998DE-1028273	
WO 9966901A2	June 8, 1999	1999WO-EP03922	
AU 9945086A	June 8, 1999	1999AU-0045086	
AU 9945086A		WO 9966901	Based on
EP 1089719A2	June 8, 1999	1999EP-0927904	
EP 1089719A2	June 8, 1999	1999WO-EP03922	
EP 1089719A2		WO 9966901	Based on
BR 9912210A	June 8, 1999	1999BR-0012210	
BR 9912210A	June 8, 1999	1999WO-EP03922	
BR 9912210A		WO 9966901	Based on
CZ 200004798A3	June 8, 1999	1999WO-EP03922	
CZ 200004798A3	June 8, 1999	2000CZ-0004798	
CZ 200004798A3		WO 9966901	Based on
ZA 200007751A	December 21, 2000	2000ZA-0007751	
KR2001053132A	December 22, 2000	2000KR-0714673	
CN 1310616A	June 8, 1999	1999CN-0808870	
HU 200102498A2	June 8, 1999	1999WO-EP03922	
HU 200102498A2	June 8, 1999	2001HU-0002498	
HU 200102498A2		WO 9966901	Based on
EP 1089719B1	June 8, 1999	1999EP-0927904	
EP 1089719B1	June 8, 1999	1999WO-EP03922	
EP 1089719B1		WO 9966901	Based on

INT-CL (IPC): A61 K 0/00; A61 K 9/00; A61 K 9/70; A61 K 31/565; A61 K 31/569; A61 K 31/57; A61 K 47/18; A61 K 47/30; A61 L 15/22; A61 L 15/44; A61 L 15/58; A61 M 37/00; A61 P 15/18

ABSTRACTED-PUB-NO: DE 19828273A

BASIC-ABSTRACT:

NOVELTY - Transdermal patch for controlled release of estradiol (I) and norethisterone acetate (II) comprises a backing layer, a reservoir that is supersaturated with active ingredients and comprises a polyacrylate adhesive and a crystallization inhibitor which is a polymer containing amino groups, and a release liner.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - The patch can be used for therapeutic purposes in human medicine (no further details given).

ADVANTAGE - The crystallization inhibitor inhibits crystallization of (I) and (II) in the reservoir.

ABSTRACTED-PUB-NO:

EP 1089719B

EQUIVALENT-ABSTRACTS:

NOVELTY - Transdermal patch for controlled release of estradiol (I) and norethisterone acetate (II) comprises a backing layer, a reservoir that is supersaturated with active ingredients and comprises a polyacrylate adhesive and a crystallization inhibitor which is a polymer containing amino groups, and a release liner.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - The patch can be used for therapeutic purposes in human medicine (no further details given).

ADVANTAGE - The crystallization inhibitor inhibits crystallization of (I) and (II) in the reservoir.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: TRANSDERMAL PATCH USEFUL CONTROL RELEASE OESTRADIOL NORETHISTERONE ACETATE

DERWENT-CLASS: A14 A96 B01 D22 G03 P34

CPI-CODES: A04-F01A1; A12-V01; B01-A02; B01-C03; B04-C03B; B12-M02D; B12-M10; D09-C; G03-B02D1;

CHEMICAL-CODES:

Chemical Indexing M5 *01*

Fragmentation Code

M424 M431 M740 M782 M904 M905 N103 R041 R051 R052

Specific Compounds

A16KGK A16KGM

Chemical Indexing M5 *02*

Fragmentation Code

M424 M431 M740 M782 M904 M905 M910 N103 R041 R051

R052

Specific Compounds

00014K 00014M

Registry Numbers

0014U

Chemical Indexing M1 *03*

Fragmentation Code

H7 H714 H721 J0 J011 J1 J171 M210 M212 M262
M281 M320 M423 M424 M430 M510 M520 M530 M540 M740
M782 M904 M905 N103 Q130

Specific Compounds

A02L0K A02L0M A037TK A037TM

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0014U

ENHANCED-POLYMER-INDEXING:

Polymer Index [1.1] 018 ; G0260*R G0022 D01 D12 D10 D26 D51 D53 ; H0000 ; S9999 S1014*R ;
S9999 S1605*R ; P0088 Polymer Index [1.2] 018 ; ND01 ; Q9999 Q8037 Q7987 ; Q9999 Q7250 Polymer
Index [1.3] 018 ; Q9999 Q6644*R ; Q9999 Q6666 Q6644 ; B9999 B4988*R B4977 B4740 ; K9869
K9847 K9790 Polymer Index [2.1] 018 ; G0395*R G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26
D51 D53 D58 D63 D88 F41 F89 ; R01606 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53
D58 D63 D88 F08 F07 F41 F89 ; R00479 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53
D58 D63 D85 F41 F89 ; H0033 H0011 ; P0088 Polymer Index [2.2] 018 ; P1105*R D01 F07 ; M9999
M2028 ; M9999 M2153*R Polymer Index [2.3] 018 ; P1105*R D01 F07 Polymer Index [2.4] 018 ;
P0964*R F34 D01 ; M9999 M2153*R Polymer Index [2.5] 018 ; G3703 G3623 P0599 D01 D11 D10 D23
D22 D31 D42 D50 D76 D86 F08 F07 F24 F28 F26 F34 Polymer Index [2.6] 018 ; ND01 ; Q9999 Q8037
Q7987 ; Q9999 Q7250 Polymer Index [2.7] 018 ; Q9999 Q9369

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-032457

Non-CPI Secondary Accession Numbers: N2000-082368

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 22. Document ID: US 20020028235 A1, WO 9729735 A1, AU 9717134 A, EP 901368 A1,
AU 706967 B, AU 9952589 A, JP 2000504697 W, NZ 330942 A, KR 99087057 A, US 6299900 B1

L1: Entry 22 of 22

File: DWPI

Mar 7, 2002

DERWENT-ACC-NO: 1997-424735

DERWENT-WEEK: 200221

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Non-occlusive, percutaneous, or transdermal drug delivery system - having
active agent, safe and approved sunscreen as penetration enhancer, and optional
volatile liquid

INVENTOR: FINNIN, B C; MORGAN, T M ; REED, B L

PATENT-ASSIGNEE:

ASSIGNEE	CODE
UNIV MONASH	MONU
FINNIN B C	FINNI
MORGAN T M	MORGI
REED B L	REEDI

PRIORITY-DATA: 1996AU-0008144 (February 19, 1996), 1999AU-0052589 (October 1, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020028235 A1	March 7, 2002		000	A61K009/70
WO 9729735 A1	August 21, 1997	E	070	A61K007/42
AU 9717134 A	September 2, 1997		000	A61K007/42
EP 901368 A1	March 17, 1999	E	000	A61K007/42
AU 706967 B	July 1, 1999		000	A61K007/42
AU 9952589 A	December 2, 1999		000	A61K007/42
JP 2000504697 W	April 18, 2000		065	A61K047/14
NZ 330942 A	November 29, 1999		000	A61K047/14
KR 99087057 A	December 15, 1999		000	A61K009/70
US 6299900 B1	October 9, 2001		000	A61K009/10

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AT BE CH DE DK EA ES FI FR GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS: AU 8930258; AU 9049984 ; AU 9191413

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
US20020028235A1	February 19, 1997	1997WO-AU00091	Div ex
US20020028235A1	December 18, 1998	1998US-0125436	Div ex
US20020028235A1	July 24, 2001	2001US-0910780	
US20020028235A1		US 6299900	Div ex
WO 9729735A1	February 19, 1997	1997WO-AU00091	
AU 9717134A	February 19, 1997	1997AU-0017134	
AU 9717134A		WO 9729735	Based on
EP 901368A1	February 19, 1997	1997EP-0904304	
EP 901368A1	February 19, 1997	1997WO-AU00091	
EP 901368A1		WO 9729735	Based on
AU 706967B	February 19, 1997	1997AU-0017134	
AU 706967B		AU 9717134	Previous Publ.
AU 706967B		WO 9729735	Based on
AU 9952589A	February 19, 1997	1997AU-0017134	Div ex
AU 9952589A	October 1, 1999	1999AU-0052589	
AU 9952589A		AU 706967	Div ex
JP2000504697W	February 19, 1997	1997JP-0528834	
JP2000504697W	February 19, 1997	1997WO-AU00091	
JP2000504697W		WO 9729735	Based on
NZ 330942A	February 19, 1997	1997NZ-0330942	
NZ 330942A	February 19, 1997	1997WO-AU00091	
KR 99087057A	February 19, 1997	1997WO-AU00091	
KR 99087057A	August 19, 1998	1998KR-0706443	
KR 99087057A		WO 9729735	Based on
US 6299900B1	February 19, 1997	1997WO-AU00091	
US 6299900B1	December 18, 1998	1998US-0125436	
US 6299900B1		WO 9729735	Based on

INT-CL (IPC): A61 K 7/42; A61 K 7/44; A61 K 9/10; A61 K 9/12; A61 K 9/70; A61 K 31/24; A61 K 47/14; A61 K 47/18

ABSTRACTED-PUB-NO: US 6299900B

BASIC-ABSTRACT:

The following are claimed:

(A) Transdermal drug delivery system, comprising (a) at least 1 physiologically active agent or prodrug (PAAP); and (b) at least 1 dermal penetration enhancer (DPE), in which the DPE is a safe, skin tolerant, ester sunscreen.

(B) Non-occlusive, percutaneous, or transdermal drug delivery system, comprising (a') at least 1 PAAP; (b') at least 1 non-volatile DPE; and (c') at least 1 volatile liquid; in which the DPE is adapted to transport the PAAP across a dermal surface or mucosal membrane, when the volatile liquid evaporates, to form a reservoir or depot of a mixture containing PAAP and DPE within the surface or membrane; and the DPE is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane.

(C) Apparatus for controlled application of an aerosol or spray composition to the dermal surface or mucosal membrane, comprising a shroud, adapted to receive the actuator nozzle of the device, which is placed on an intended site of application, in which the shroud keeps the nozzle at a predetermined height above the site of application.

USE - The system (A) is normally used in the form of a patch for drug delivery, although (B), as stated, can be non-occlusive. A wide range of systemic drugs can be delivered by either variant of the method, including steroid, hormone derivative, non-steroidal antiinflammatory, opioid analgesic, anti-nauseant, anti-oestrogen, aromatase- or 5-alpha reductase inhibitor, anxiolytic, prostaglandin, antiviral, antimigraine, antihypertensive, antimalarial, bronchodilator, anti-Alzheimer, anti-Parkinson, neuroleptic, antipsychotic, antiandrogen, or anorectic drugs.

Uses of these drugs are for female or male contraception, hormone replacement in testosterone deficient men, or in post-menopausal women, androgen replacement for females lacking libido, or in oestrogen dependent breast cancer; non-hormonal uses are for soft tissue injury, narcotic withdrawal, post-operative pain, motion sickness, prostatic enlargement and/or cancer, alopecia, acne, anxiety, impotence, Raynaud's syndrome, varicose veins, sleep disorders and jet-lag, herpes infections, deep vein thrombosis, migraine, high blood pressure, malaria, cystic fibrosis diagnosis, or asthma. Also noted in the disclosure are insecticides and pesticides for local or systemic application.

Specifically named drugs are testosterone, oestradiol, ethinyl-oestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstenedione and derivatives, finasteride, turosteride, LY191704, MK-306, alprazolam, alprostadil, prostacyclin and derivatives, melatonin, n-docosanol, tromantidine, lipophilic prodrugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil and prodrugs, pilocarpine, salbutamol, salmeterol, terbutaline, ibogaine, bupropion, rolipram, tacrine, fluphenazine, haloperidol, N-0923, cyproterone acetate, or mazindol.

The shroud (C) attached to an aerosol or spray device, can keep the nozzle perpendicular to the surface being treated, and encloses the area, to contain the aerosol or spray; preferably, the area defined by the shroud is circular.

ADVANTAGE - The ester sunscreens, see (A) above, and particularly those named below, have already been tested, considered safe and non-irritating by the US FDA, and used extensively for 10-20 years in sunscreen compositions. By contrast, DPE in common use, e.g., Azone, DMSO, and DMAc, may be irritant, allergenic, or even toxic. The system is also not supersaturated with respect to drug, which can cause problems. In (B), use of a volatile solvent which evaporates rapidly, leaving the surface 'touch dry', and the other constituents in the skin, avoid accidental transfer to other areas 'messiness', or other individuals. This is a particular point in hormone compositions. The shroud (C) prevents or limits 'bounce-back' and/or loss of drug

into the air.
ABSTRACTED-PUB-NO:

US20020028235A
EQUIVALENT-ABSTRACTS:

The following are claimed:

(A) Transdermal drug delivery system, comprising (a) at least 1 physiologically active agent or prodrug (PAAP); and (b) at least 1 dermal penetration enhancer (DPE); in which the DPE is a safe, skin tolerant, ester sunscreen.

(B) Non-occlusive, percutaneous, or transdermal drug delivery system, comprising (a') at least 1 PAAP; (b') at least 1 non-volatile DPE; and (c') at least 1 volatile liquid; in which the DPE is adapted to transport the PAAP across a dermal surface or mucosal membrane, when the volatile liquid evaporates, to form a reservoir or depot of a mixture containing PAAP and DPE within the surface or membrane; and the DPE is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane.

(C) Apparatus for controlled application of an aerosol or spray composition to the dermal surface or mucosal membrane, comprising a shroud, adapted to receive the actuator nozzle of the device, which is placed on an intended site of application, in which the shroud keeps the nozzle at a predetermined height above the site of application.

USE - The system (A) is normally used in the form of a patch for drug delivery, although (B), as stated, can be non-occlusive. A wide range of systemic drugs can be delivered by either variant of the method, including steroid, hormone derivative, non-steroidal antiinflammatory, opioid analgesic, anti-nauseant, anti-oestrogen, aromatase- or 5-alpha reductase inhibitor, anxiolytic, prostaglandin, antiviral, antimigraine, antihypertensive, antimalarial, bronchodilator, anti-Alzheimer, anti-Parkinson, neuroleptic, antipsychotic, antiandrogen, or anorectic drugs.

Uses of these drugs are for female or male contraception, hormone replacement in testosterone deficient men, or in post-menopausal women, androgen replacement for females lacking libido, or in oestrogen dependent breast cancer; non-hormonal uses are for soft tissue injury, narcotic withdrawal, post-operative pain, motion sickness, prostatic enlargement and/or cancer, alopecia, acne, anxiety, impotence, Raynaud's syndrome, varicose veins, sleep disorders and jet-lag, herpes infections, deep vein thrombosis, migraine, high blood pressure, malaria, cystic fibrosis diagnosis, or asthma. Also noted in the disclosure are insecticides and pesticides for local or systemic application.

Specifically named drugs are testosterone, oestradiol, ethinyl-oestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstenedione and derivatives, finasteride, turosteride, LY191704, MK-306, alprazolam, alprostadil, prostacyclin and derivatives, melatonin, n-docosanol, tromantidine, lipophilic prodrugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil and prodrugs, pilocarpine, salbutamol, salmeterol, terbutaline, ibogaine, bupropion, rolipram, tacrine, fluphenazine, haloperidol, N-0923, cyproterone acetate, or mazindol.

The shroud (C) attached to an aerosol or spray device, can keep the nozzle perpendicular to the surface being treated, and encloses the area, to contain the aerosol or spray; preferably, the area defined by the shroud is circular.

ADVANTAGE - The ester sunscreens, see (A) above, and particularly those named below, have already been tested, considered safe and non-irritating by the US FDA, and used extensively for 10-20 years in sunscreen compositions. By contrast, DPE in common use, e.g., Azone, DMSO, and DMAc, may be irritant, allergenic, or even toxic. The system is also not supersaturated with respect to drug, which can cause problems. In (B), use of a volatile solvent which evaporates rapidly, leaving the surface 'touch dry', and the other constituents in the skin, avoid accidental transfer to other areas

'messiness'', or other individuals. This is a particular point in hormone compositions. The shroud (C) prevents or limits 'bounce-back' and/or loss of drug into the air.

The following are claimed:

(A) Transdermal drug delivery system, comprising (a) at least 1 physiologically active agent or prodrug (PAAP); and (b) at least 1 dermal penetration enhancer (DPE), in which the DPE is a safe, skin tolerant, ester sunscreen.

(B) Non-occlusive, percutaneous, or transdermal drug delivery system, comprising (a') at least 1 PAAP; (b') at least 1 non-volatile DPE; and (c') at least 1 volatile liquid; in which the DPE is adapted to transport the PAAP across a dermal surface or mucosal membrane, when the volatile liquid evaporates, to form a reservoir or depot of a mixture containing PAAP and DPE within the surface or membrane; and the DPE is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane.

(C) Apparatus for controlled application of an aerosol or spray composition to the dermal surface or mucosal membrane, comprising a shroud, adapted to receive the actuator nozzle of the device, which is placed on an intended site of application, in which the shroud keeps the nozzle at a predetermined height above the site of application.

USE - The system (A) is normally used in the form of a patch for drug delivery, although (B), as stated, can be non-occlusive. A wide range of systemic drugs can be delivered by either variant of the method, including steroid, hormone derivative, non-steroidal antiinflammatory, opioid analgesic, anti-nauseant, anti-oestrogen, aromatase- or 5-alpha reductase inhibitor, anxiolytic, prostaglandin, antiviral, antimigraine, antihypertensive, antimalarial, bronchodilator, anti-Alzheimer, anti-Parkinson, neuroleptic, antipsychotic, antiandrogen, or anorectic drugs.

Uses of these drugs are for female or male contraception, hormone replacement in testosterone deficient men, or in post-menopausal women, androgen replacement for females lacking libido, or in oestrogen dependent breast cancer; non-hormonal uses are for soft tissue injury, narcotic withdrawal, post-operative pain, motion sickness, prostatic enlargement and/or cancer, alopecia, acne, anxiety, impotence, Raynaud's syndrome, varicose veins, sleep disorders and jet-lag, herpes infections, deep vein thrombosis, migraine, high blood pressure, malaria, cystic fibrosis diagnosis, or asthma. Also noted in the disclosure are insecticides and pesticides for local or systemic application.

Specifically named drugs are testosterone, oestradiol, ethinyl-oestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstenedione and derivatives, finasteride, turosteride, LY191704, MK-306, alprazolam, alprostadil, prostacyclin and derivatives, melatonin, n-docosanol, tromantidine, lipophilic prodrugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil and prodrugs, pilocarpine, salbutamol, salmeterol, terbutaline, ibogaine, bupropion, rolipram, tacrine, fluphenazine, haloperidol, N-0923, cyproterone acetate, or mazindol.

The shroud (C) attached to an aerosol or spray device, can keep the nozzle perpendicular to the surface being treated, and encloses the area, to contain the aerosol or spray; preferably, the area defined by the shroud is circular.

ADVANTAGE - The ester sunscreens, see (A) above, and particularly those named below, have already been tested, considered safe and non-irritating by the US FDA, and used extensively for 10-20 years in sunscreen compositions. By contrast, DPE in common use, e.g., Azone, DMSO, and DMAc, may be irritant, allergenic, or even toxic. The system is also not supersaturated with respect to drug, which can cause problems. In (B), use of a volatile solvent which evaporates rapidly, leaving the surface 'touch dry', and the other constituents in the skin, avoid accidental transfer to other areas 'messiness'', or other individuals. This is a particular point in hormone compositions. The shroud (C) prevents or limits 'bounce-back' and/or loss of drug

into the air.

WO 9729735A

CHOSEN-DRAWING: Dwg.0/9

TITLE-TERMS: NON OCCLUDE PERCUTANEOUS TRANSDERMAL DRUG DELIVER SYSTEM ACTIVE AGENT
SAFE APPROVE SUNSCREEN PENETRATE ENHANCE OPTION VOLATILE LIQUID

DERWENT-CLASS: B07 C07

CPI-CODES: B01-A02; C01-A02; B01-C04; C01-C04; B01-C05; C01-C05; B01-D02; C01-D02;
B04-A01; C04-A01; B04-A04; C04-A04; B04-C02E1; C04-C02E1; B06-H; C06-H; B07-H; C07-H;
B10-B04; C10-B04; B10-C03; C10-C03; B10-C04B; C10-C04B; B14-A02; C14-A02; B14-A03B;
C14-A03B; B14-C01; C14-C01; B14-D01; C14-D01; B14-F02B; C14-F02B; B14-F04; C14-F04;
B14-H01; C14-H01; B14-J01; C14-J01; B14-K01; C14-K01;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

G010 G011 G012 G013 G014 G015 G016 G100 H102 H103
H401 H402 H441 H442 H541 H542 H600 H608 H641 H642
H721 J0 J011 J2 J231 J271 M210 M211 M212 M213
M214 M215 M216 M220 M221 M222 M223 M224 M225 M226
M231 M232 M233 M240 M272 M273 M281 M282 M283 M311
M312 M320 M321 M332 M342 M372 M391 M414 M431 M510
M520 M531 M540 M782 M903 M904 P210 P312 P411 P444
P446 P448 P526 P611 P616 P625 P822 P943 Q263 V810
Markush Compounds
199739-23801-M

Chemical Indexing M2 *02*

Fragmentation Code

D011 D013 D931 H1 H100 H121 H181 H2 H201 H4
H401 H481 H5 H581 H8 J5 J521 K0 L6 L640
L9 L910 M280 M311 M312 M321 M332 M342 M373 M383
M391 M412 M431 M511 M520 M530 M540 M782 M903 M904
P210 P312 P411 P444 P446 P448 P526 P611 P616 P625
P822 P943 Q263 V810
Specific Compounds
04178M

Chemical Indexing M2 *03*

Fragmentation Code

D011 D021 D029 D030 E570 G030 G530 H1 H181 H2
H201 H4 H402 H441 H481 H5 H561 H8 M210 M211
M272 M281 M311 M315 M321 M333 M340 M342 M373 M392
M412 M431 M511 M520 M530 M541 M782 M800 M903 M904
P210 P312 P411 P444 P446 P448 P526 P611 P616 P625
P822 P943 Q263 V0 V441 V810
Ring Index
06766
Specific Compounds
04282M

Chemical Indexing M2 *04*

Fragmentation Code

G011 G014 G100 H1 H102 H141 H6 H602 H608 H642
J0 J011 J1 J171 M121 M143 M280 M311 M321 M342
M372 M391 M414 M431 M510 M520 M532 M540 M782 M903
M904 P210 P312 P411 P444 P446 P448 P526 P611 P616
P625 P822 P943 Q263 V810
Specific Compounds

03008M

Chemical Indexing M2 *05*

Fragmentation Code

F011 F014 F433 G010 G019 G100 H1 H181 H2 H201
J0 J011 J3 J321 M1 M123 M143 M210 M212 M262
M281 M312 M321 M332 M342 M373 M391 M413 M431 M510
M521 M532 M540 M782 M903 M904 M910 P210 P312 P411
P444 P446 P448 P526 P611 P616 P625 P822 P943 Q263
V810

Specific Compounds

01254M

Registry Numbers

1254U

Chemical Indexing M2 *06*

Fragmentation Code

G010 G015 G100 H6 H601 H641 J0 J011 J1 J171
M1 M111 M280 M312 M321 M331 M340 M342 M372 M391
M414 M431 M510 M520 M532 M540 M782 M903 M904 P210
P312 P411 P444 P446 P448 P526 P611 P616 P625 P822
P943 Q263 V810

Specific Compounds

04393M

Chemical Indexing M2 *07*

Fragmentation Code

G013 G100 J0 J011 J1 J171 M210 M214 M232 M240
M281 M312 M321 M331 M340 M342 M372 M391 M414 M431
M510 M520 M531 M540 M782 M903 M904 M910 P210 P312
P411 P444 P446 P448 P526 P611 P616 P625 P822 P943
Q263 V810

Specific Compounds

01987M

Registry Numbers

1987U

Chemical Indexing M2 *08*

Fragmentation Code

G010 G013 G100 J0 J011 J1 J171 J4 J431 M1
M121 M131 M280 M312 M321 M331 M340 M342 M372 M391
M414 M431 M510 M520 M532 M540 M782 M903 M904 P210
P312 P411 P444 P446 P448 P526 P611 P616 P625 P822
P943 Q263 V810

Specific Compounds

03908M

Chemical Indexing M2 *09*

Fragmentation Code

D011 D022 D601 H5 H541 H8 J0 J011 J3 J371
M210 M211 M262 M272 M281 M312 M321 M332 M342 M373
M391 M412 M431 M511 M520 M530 M540 M782 M903 M904
M910 P210 P312 P411 P444 P446 P448 P526 P611 P616
P625 P822 P943 Q263 V810

Specific Compounds

00320M

Registry Numbers

0320U

Chemical Indexing M2 *10*

Fragmentation Code

D011 D023 E100 F011 F012 F521 H1 H182 H2 H202
J5 J561 M210 M211 M240 M273 M281 M311 M321 M342
M373 M391 M412 M431 M511 M521 M530 M540 M782 M903
M904 P210 P312 P411 P444 P446 P448 P526 P611 P616

P625 P822 P943 Q263 V810
Specific Compounds
11141M

Chemical Indexing M2 *11*

Fragmentation Code

F011 F012 F013 F014 F019 F113 F521 H1 H181 H2
H201 J5 J521 L9 L942 M1 M126 M132 M210 M211
M212 M240 M273 M281 M311 M321 M342 M413 M431 M510
M522 M530 M540 M782 M903 M904 M910 P210 P312 P411
P444 P446 P448 P526 P611 P616 P625 P822 P943 Q263
V810

Specific Compounds

00593M

Registry Numbers

0593U

Chemical Indexing M2 *12*

Fragmentation Code

D011 D022 E800 F011 F014 F553 H1 H183 H2 H203
H6 H602 H641 M210 M211 M273 M281 M313 M321 M332
M342 M383 M391 M412 M431 M511 M521 M530 M540 M782
M903 M904 P210 P312 P411 P444 P446 P448 P526 P611
P616 P625 P822 P943 Q263 V810

Specific Compounds

04402M

Chemical Indexing M2 *13*

Fragmentation Code

D011 D023 D130 H4 H402 H461 H481 H8 J0 J011
J1 J171 M280 M314 M315 M321 M331 M332 M342 M372
M373 M391 M412 M431 M511 M520 M530 M540 M782 M903
M904 P210 P312 P411 P444 P446 P448 P526 P611 P616
P625 P822 P943 Q263 V0 V622 V810

Ring Index

01010

Specific Compounds

03935M

Chemical Indexing M2 *14*

Fragmentation Code

D011 D013 E500 G010 G100 H1 H181 H2 H201 H4
H401 H481 H8 J0 J011 J2 J221 M210 M211 M273
M281 M312 M321 M332 M343 M371 M391 M412 M431 M511
M520 M531 M540 M782 M903 M904 M910 P210 P312 P411
P444 P446 P448 P526 P611 P616 P625 P822 P943 Q263
V0 V411 V810

Specific Compounds

00046M

Registry Numbers

0046U

Chemical Indexing M2 *15*

Fragmentation Code

G010 G013 G019 G100 H1 H103 H181 H5 H541 H7
H721 H8 M1 M121 M129 M132 M133 M150 M210 M211
M273 M282 M312 M314 M321 M331 M332 M342 M343 M383
M391 M414 M431 M510 M520 M533 M540 M782 M903 M904
P210 P312 P411 P444 P446 P448 P526 P611 P616 P625
P822 P943 Q263 V810

Specific Compounds

04292M

Chemical Indexing M5 *16*

Fragmentation Code

M431 M782 M903 M904 P210 P312 P411 P444 P446 P448
P526 P611 P616 P625 P822 P943 Q263 S001 S003 S005
S030 S033 S050 S132 S133 S134 S142 S143 S217 S503
S517 U500 U501
Specific Compounds
06173M

Chemical Indexing M5 *17*

Fragmentation Code

M431 M782 M903 M904 M910 P210 P312 P411 P444 P446
P448 P526 P611 P616 P625 P822 P943 Q263 S004 S132
S133 S134 S142 S143 S317 S603 S620 U520 U521

Specific Compounds

00145M

Registry Numbers

0145U

Chemical Indexing M5 *18*

Fragmentation Code

M431 M782 M903 M904 M910 P210 P312 P411 P444 P446
P448 P526 P611 P616 P625 P822 P943 Q263 S004 S132
S133 S134 S142 S143 S317 S517 S603 U500 U501

Specific Compounds

00156M

Registry Numbers

0156U

Chemical Indexing M1 *19*

Fragmentation Code

C316 J0 J011 J111 K0 K3 K340 K4 K421 M423
M431 M782 M903 M904 M910 P210 P312 P411 P444 P446
P448 P526 P611 P616 P625 P822 P943 Q263 V732 V810

Specific Compounds

01867M

Registry Numbers

1867U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0046U; 0145U ; 0156U ; 0320U ; 0593U ; 1254U ;
1867U ; 1987U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1997-135871

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Clip Img	Image											

[Generate Collection](#)[Print](#)

Term	Documents
TRANSDERMAL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	19898
TRANSDERMALS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	10
PATCH.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	43430
PATCHES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	25683
PALSTER.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	9
PALSTERS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
SUPERSATURAT\$4	0
SUPERSATURAT.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	34
SUPERSATURATE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	320
SUPERSATURATECT.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
(((((TRANSDERMAL OR PATCH OR PALSTER))AND (SUPERSATURAT\$4 OR SARURAT\$4 OR OVERSATURAT\$4 OR OVER SATURAT\$4)) AND (ESTROGEN OR EOSTROGEN OR ESTRADIOL OR OESTRADIOL) AND NORETHISTERONE))).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	22

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

-

[Change Format](#)

[Previous Page](#)

[Next Page](#)